Please login to the form below

Not currently logged in
Email:
Password:

NICE grants final approval to Shire's Resolor

NICE has granted approval for Resolor to be used by the NHS for treatment of certain trypes of chronic constipation

The National Institure for Health and Clinical Excellence (NICE) has granted final approval for Resolor (prucalopride) to be used by the NHS for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief

The drug has been recommended where treatment with at least two laxatives from different classes at the highest tolerated recommended doses for at least six months, has failed to provide adequate relief and invasive treatment for constipation is being considered. 

Resolor is the first selective high-affinity serotonin (5-HT4) receptor agonist, which unlike laxatives directly stimulates receptors involved in gut motility, thereby helping to restore normal bowel movements.

Dr Anton Emmanuel, consultant gastroenterologist & senior lecturer in neurogastroenterology commented: "The NICE appraisal of prucalopride is a significant development in the management of chronic constipation in women. It offers these long-suffering female patients a novel alternative where laxatives have failed to improve symptoms.

"For these individuals the alternatives may have been invasive hospital-based therapies, so the drug has a discrete place in the treatment pathway. The drug represents the first in this class of treatment for patients with functional gastrointestinal disorders for over 25 years."

20th December 2010

From: Healthcare

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics